Settlement Valuation: The Hidden Cost of Future Medical Care

Introduction: Why Future Medical Often Determines Settlement Value

In workers’ compensation settlements, indemnity benefits are visible, quantifiable, and finite. Future medical care, by contrast, is often abstract—described vaguely in medical reports and discounted during negotiations until it resurfaces years later as an unexpected cost.

Yet in many cases, future medical exposure is the single largest driver of settlement value. Underestimating it can result in premature resolutions that fail to reflect long-term risk. Overestimating it can stall negotiations unnecessarily.

This article examines why future medical care is frequently undervalued, how to identify hidden medical exposure, and what practitioners should consider when incorporating future care into settlement valuation.

---

The Structural Problem: Future Medical Is Inherently Uncertain

Unlike permanent disability, future medical care is speculative by design. It depends on:

• Disease progression
• Treatment compliance
• Advances in medical care
• Changes in utilization patterns
• Claimant behavior

Medical-legal reports often hedge, using language such as:

• “May require future care”
• “Could benefit from ongoing treatment”
• “Will likely need intermittent treatment”

These phrases are easy to gloss over—but each represents potential long-term financial exposure.

---

Why Future Medical Gets Discounted in Negotiations

There are several reasons future medical care is routinely undervalued:

1. Lack of Immediate Cash Impact Indemnity payments feel tangible. Future medical does not—until treatment resumes post-settlement.
2. Vague Medical Reporting QMEs often identify future care in general terms without cost estimates or treatment frequency.
3. Assumption of Claim Closure Parties subconsciously assume treatment will taper off, even when medical evidence suggests otherwise.
4. Focus on Rating-Based Valuation Many settlement discussions revolve around PD ratings while future medical remains an afterthought.

This structural bias can materially distort case valuation.

---

Common Categories of Hidden Future Medical Exposure

Future medical exposure is rarely limited to routine office visits. Common categories include:

• Chronic pain management (medications, injections)
• Physical therapy or functional restoration programs
• Orthopedic hardware removal or revision surgeries
• Progressive degenerative conditions
• Psychiatric or psychological treatment as a compensable consequence
• Durable medical equipment or assistive devices

Each category carries different cost trajectories and utilization patterns.

---

The Long Tail of Medical Costs

One of the most overlooked aspects of future medical care is its long tail.

Even modest, intermittent treatment—when projected over decades—can eclipse the value of indemnity benefits. This is particularly true in cases involving:

• Younger injured workers
• Chronic orthopedic conditions
• Spine injuries
• Progressive or degenerative pathology

A $2,000 annual treatment cost over 20 years is no longer incidental—it is a material settlement component.

---

Medical-Legal Reporting: Reading Between the Lines

Effective valuation requires more than reading conclusions. It requires analyzing what the report implies, not just what it states.

Key questions to ask when reviewing medical reports:

• What treatments are identified, even conditionally?
• Are future surgeries discussed but minimized?
• Does the physician acknowledge symptom progression?
• Is the injured worker considered medically stable—or merely at MMI?

A report stating that surgery is “not recommended at this time” is not the same as ruling it out permanently.

---

Medicare Set-Asides and Federal Overlay Risk

In cases involving Medicare beneficiaries or likely future beneficiaries, future medical valuation takes on additional complexity.

Medicare Set-Asides (MSAs):

• Require careful identification of covered future medical expenses
• Often reveal medical exposure underestimated in negotiations
• Can significantly increase settlement funding requirements

Even when an MSA is not formally required, its analysis often exposes true medical cost expectations that inform realistic valuation.

---

Strategic Use of Cost Projections

Sophisticated settlement analysis incorporates cost modeling—not guesswork.

Cost projections may include:

• Life care plans
• Treatment frequency estimates
• Medication cost escalation
• Surgical probability analysis

While not required in every case, cost projections are particularly useful when:

• Future care is disputed
• Exposure is substantial
• Settlement negotiations are stalled

They shift the discussion from abstract risk to concrete numbers.

---

Future Medical as Leverage—For Both Sides

Future medical exposure cuts both ways.

For applicants’ counsel, it can:

• Support higher settlement demands
• Justify keeping medical open
• Strengthen arguments against premature C&R

For defense counsel and carriers, it can:

• Highlight long-term cost certainty benefits of settlement
• Justify structured settlements
• Support negotiated medical buyouts

The key is transparency. Hidden exposure benefits no one long term.

---

Integrating Legal Research and Case Data

WCAB decisions repeatedly emphasize that future medical determinations must be supported by substantial evidence. Case law addressing medical necessity, reasonableness, and apportionment directly informs valuation.

Practitioners who integrate:

• Medical records
• Medical-legal opinions
• Applicable case law

into a single analytical workflow are better positioned to assess true exposure and negotiate from an informed position.

---

Technology’s Role in Smarter Valuation

As case files grow larger and medical histories more complex, manual review becomes inefficient and error-prone.

Modern legal intelligence platforms allow practitioners to:

• Identify future medical references across entire case files
• Compare similar cases and outcomes
• Surface relevant case law tied to medical issues
• Draft settlement analyses grounded in evidence

This reduces blind spots and supports defensible valuation decisions.

---

Conclusion: Future Medical Is Not an Afterthought

Future medical care is not speculative fluff—it is a core component of workers’ compensation settlement valuation.

Ignoring it risks undervaluing exposure. Overreacting to it risks derailing resolution. The goal is disciplined analysis grounded in medical evidence, legal standards, and realistic cost expectations.

When future medical care is properly identified and evaluated, settlements become more predictable, defensible, and durable—serving the interests of all parties involved.